The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Assessment of FOXC1 expression as a predictor of response to neoadjuvant taxane plus platinum regimens in primary triple-negative breast cancer: Retrospective analysis of three clinical trial cohorts.
 
Partha Ray
Leadership - Onconostic Technologies
Stock and Other Ownership Interests - Onconostic Technologies
Consulting or Advisory Role - Onconostic Technologies
Patents, Royalties, Other Intellectual Property - Onconostic Technologies
 
Tania Ray
Stock and Other Ownership Interests - Onconostic Technologies
 
Sara Lopez-Tarruella Cobo
Consulting or Advisory Role - AstraZeneca; Daiichi Sankyo Europe GmbH; Gilead Sciences; GlaxoSmithKline; Lilly; MSD; Novartis; Pfizer; Pierre Fabre; Roche; Seagen; Veracyte
Speakers' Bureau - Lilly
 
Maria del Monte Millan
No Relationships to Disclose
 
Enrique Álvarez
No Relationships to Disclose
 
Yolanda Jerez Gilarranz
Honoraria - AstraZeneca; Novartis; Roche
Consulting or Advisory Role - AstraZeneca; Novartis; Pfizer; Roche
Travel, Accommodations, Expenses - Novartis; Pfizer; Roche; Teva
 
Marta Roche
No Relationships to Disclose
 
Clive R. Taylor
Stock and Other Ownership Interests - Onconostic Technologies
Consulting or Advisory Role - Onconostic Technologies
 
Miguel Martin
Honoraria - Lilly; Novartis; Pfizer; Pierre Fabre; Roche/Genentech; Seagen
Consulting or Advisory Role - AstraZeneca; Daiichi-Sankyo; Lilly; Novartis; Pfizer; Roche/Genentech
Speakers' Bureau - Lilly/ImClone; Lilly/ImClone; Pierre Fabre; Roche/Genentech
Research Funding - Novartis (Inst); Puma Biotechnology (Inst); Roche (Inst)
Other Relationship - Novartis; Roche